Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp

Bullboard Posts

Post by SanFrancisco99on Jul 22, 2014 11:08am

236 Views

Post# 22769492

Thank You Bear For Correction

Bear: Thank you for correcting me. I am glad to know that Zenith is also
presenting tomorrow - not just same-old, same-old about RVX-208. I
(obviously) did not see that!

Hopefully there will be a news release tomorrow to tell us something
about what is being presented on Zenith. Hopefully it will include some
new and concrete information.

If they are going to do an IPO someday, they are going to have to start
communicating with us about what they have. The stealth thing is getting old.

Bullboard Posts

Paramount Resources signs $3.32 billion asset sale